OrthoPediatrics FY 2023 revenue $148.7M (+22% YoY); guides FY 2024 rev $197-200M

ORTHOPEDIATRICS CORP

FY 2023 net loss $21.0M ($0.92/share) vs net income $1.3M ($0.06) in 2022; adjusted EBITDA rose to $5.0M from $0.2M.
Q4 2023 revenue $37.6M (+21% YoY); gross margin 71.0% vs 68.5%; U.S. revenue +24%, international +13%.
FY 2024 revenue guidance $197-200M (+32-34%); adjusted EBITDA guidance $8-9M.
Acquired Boston Orthotics & Prosthetics with $80M debt financing; post-close cash ~$60M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ORTHOPEDIATRICS CORP reported the full year ended December 31, 2023 results: revenue $148.7 million. Guidance reaffirmed.

Period: the full year ended December 31, 2023
Revenue: $148.7 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Record full year 2023 revenue of $148.7 million increased 22% compared to prior year

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ORTHOPEDIATRICS CORP reported the fourth quarter ended December 31, 2023 results: revenue $37.6 million. Guidance reaffirmed.

Period: the fourth quarter ended December 31, 2023
Revenue: $37.6 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Generated total revenue of $37.6 million for fourth quarter 2023, up 21% from $31.0 million in fourth quarter 2022

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ORTHOPEDIATRICS CORP reported full year 2024 results: revenue $197.0 million to $200.0 million. Guidance reaffirmed.

Period: full year 2024
Revenue: $197.0 million to $200.0 million
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Reiterated full year 2024 revenue guidance to be in a range of $197.0 million to $200.0 million

View on SEC.gov

Browse all earnings releases →

ORTHOPEDIATRICS CORP filing history →

Source: SEC EDGAR

accession 0001425450-24-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.